Shubhakruth Medical Genetics Preloader

Predict • Prevent • Treat Disease

Health City, Chinagadili, Visakhapatnam – 530040 Helpline: +91 94944 67890 / +91 891 3500200
Incubated at VFSTR TBI Clinician Portal Visit Lab
COMPREHENSIVE GENOMICS & DIAGNOSTICS

Clinical Genetic Diagnostics & Specialties

From preconception screening and non-invasive prenatal testing to whole exome sequencing and precision oncology, our specialized laboratory delivers actionable genomic reports grounded in ACMG guidelines.

Interactive Diagnostic Assistant

Find Your Ideal Genetic Test

Answer 2 quick questions to identify the clinically recommended NGS panel, sample tube, and turnaround time.

Step 1 of 3: Specialty Domain Personalized Match

Select Your Clinical Area of Concern:

Prenatal & Pregnancy

NIPT, Down Syndrome, Carrier screening & POC

Hereditary Oncology

BRCA1/2, Lynch Syndrome & Tumor profiling

Pediatric & Rare Disease

Exome sequencing, syndromic delays & CMA

Cardio & Neurogenetics

Cardiomyopathy, Ataxia, Neuropathy panels

Pharmacogenomics (PGx)

Drug sensitivity, metabolism & toxicity profiling

Clinical Risk Assessment Tool

Hereditary Genetic Risk Screener

Evaluate your personal and family history indicators to estimate your hereditary risk tier and identify clinically actionable genetic tests.

1 What is your primary area of health or family concern?

Hereditary Cancer Risk

Breast, Ovarian, Colon, Pancreatic, or Lynch Syndrome

Cardiomyopathy & Sudden Cardiac Death

HCM, DCM, Long QT, Brugada, or unexplained syncope

Prenatal & Couple Carrier Status

Recurrent pregnancy loss, IVF preparation, Thalassemia, SMA

Rare Syndromes & Neurodevelopment

Developmental delay, autism, neuromuscular, metabolic

Section 01

Prenatal, Fetal & Reproductive Genetics

We provide prospective parents and obstetricians with advanced non-invasive and invasive genomic diagnostics to assess chromosomal and monogenic risks early in pregnancy.

Non-Invasive Prenatal Testing (NIPT / cfDNA)

Screens cell-free fetal DNA from maternal blood for Trisomy 21 (Down Syndrome), 18 (Edwards), 13 (Patau), sex chromosome aneuploidies (Turner, Klinefelter), and microdeletions from as early as 9 weeks. Sensitivity >99%.

Sample: 10 ml Streck BCT Maternal Blood • TAT: 7-9 Days

Couple Expanded Carrier Screening Panel (500+ Genes)

Pre-conceptional screening for asymptomatic carriers of severe autosomal recessive and X-linked conditions (Beta-Thalassemia, Spinal Muscular Atrophy, Cystic Fibrosis, CAH, Fragile X).

Sample: 3 ml EDTA Blood from Both Partners • TAT: 14-18 Days

Products of Conception (POC) Microarray & QF-PCR

Evaluates chromosomal causes of recurrent miscarriage and fetal loss without maternal cell contamination artifacts.

Sample: Fresh POC Tissue in Saline • TAT: 8-12 Days

Clinical Indications for Prenatal Screening:

  • Advanced maternal age (≥30 years)
  • Abnormal first/second-trimester biochemical screen
  • Fetal ultrasound soft markers or structural anomalies
  • History of recurrent pregnancy loss (≥2 miscarriages)
  • Consanguineous marriage / family history of genetic disorder
Section 02

Whole Exome Sequencing & Rare Diseases

Gold-standard Next-Generation Sequencing platforms enabling diagnostic closure for children and adults with unexplained syndromic, neurological, or metabolic disorders.

Whole Exome Sequencing (WES Trio / Solo)

Exonic capture of ~20,000 coding genes with >100x mean depth. Trio sequencing (Proband + Parents) enables rapid de novo and compound heterozygous variant identification.

Sample: 3-5 ml EDTA Blood • TAT: 14-18 Days

Clinical Exome Sequencing (CES - 6,500+ Genes)

High-depth sequencing targeting all medically characterized human disease genes in the OMIM catalog. Cost-effective first-tier test for heterogeneous presentations.

Sample: 3 ml EDTA Blood • TAT: 12-15 Days

Mitochondrial Genome Sequencing (Full mtDNA)

Complete sequencing of the 16.5 kb mitochondrial genome to identify low-level heteroplasmy in Leigh syndrome, MELAS, and mitochondrial myopathies.

Sample: 3 ml EDTA Blood • TAT: 12-14 Days

Key Diagnostic Capabilities:

  • High-depth Illumina NovaSeq sequencing
  • ACMG/AMP 5-tier variant classification (Pathogenic to Benign)
  • Secondary findings screening per ACMG SF v3.2 recommendations
  • Familial Sanger segregation confirmation included for actionable findings
Section 03

Hereditary & Somatic Oncology Genetics

Empowering oncologists and patients with precision risk stratification, PARP-inhibitor qualification, and targeted therapeutic roadmap profiling.

Hereditary Breast & Ovarian Cancer Panel (HBOC)

Full gene sequencing and MLPA CNV analysis for BRCA1, BRCA2, PALB2, TP53, PTEN, CDH1, CHEK2, and ATM for risk assessment and surgical planning.

Sample: 3-4 ml EDTA Blood • TAT: 10-14 Days

Hereditary Colorectal & Lynch Syndrome Panel

Analyzes mismatch repair genes MLH1, MSH2, MSH6, PMS2, EPCAM, APC, and MUTYH for familial polyposis and non-polyposis colorectal cancer syndromes.

Sample: 3-4 ml EDTA Blood • TAT: 12-14 Days

Comprehensive Somatic Solid Tumor NGS Panel (52 Genes)

High-depth FFPE tissue tumor profiling evaluating actionable mutations and fusions in EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK, PIK3CA, and ERBB2.

Sample: FFPE Tumor Tissue Block • TAT: 14-16 Days

Who Should Undergo Cancer Genetic Testing?

  • Early onset breast, ovarian, or colon cancer (age < 50)
  • Multiple primary tumors diagnosed in one individual
  • Two or more close relatives with related cancers
  • Triple-negative breast cancer diagnosis
  • Men with breast cancer or metastatic prostate cancer
Section 04

Cardiogenetics & Neurogenetics

Targeted multigene panels identifying causal mutations in inherited sudden cardiac death syndromes, cardiomyopathies, and progressive neuromuscular disorders.

Inherited Cardiomyopathy & Channelopathy Panel (120+ Genes)

Evaluates Hypertrophic Cardiomyopathy (MYH7, MYBPC3), Dilated Cardiomyopathy (TTN, LMNA), Long QT Syndrome (KCNQ1, KCNH2, SCN5A), and Brugada Syndrome.

Sample: 3-5 ml EDTA Blood • TAT: 14-16 Days

Neuromuscular & Ataxia Gene Panel (180+ Genes)

Covers Limb-Girdle Muscular Dystrophies, Charcot-Marie-Tooth neuropathies, Hereditary Spastic Paraplegia, and Spinocerebellar Ataxias.

Sample: 3-5 ml EDTA Blood • TAT: 14-18 Days

Preventing Sudden Cardiac Death:

Early genetic identification enables proactive ICD (Implantable Cardioverter-Defibrillator) placement, targeted beta-blocker therapy, and cascade family member screening.

Section 05

Pharmacogenomics (PGx) Personalized Medicine

Eliminating trial-and-error prescribing. Our PGx panel tests over 25 critical drug metabolism enzymes to guide dosage and prevent life-threatening adverse drug reactions across 150+ common drugs.

Key Gene-Drug Interactions Tested:

CYP2C19: Clopidogrel & Antidepressants
CYP2D6: Beta-blockers, Tamoxifen & Codeine
VKORC1 / CYP2C9: Warfarin Anticoagulation
SLCO1B1: Statin-induced Myopathy
TPMT / NUDT15: Thiopurine / Azathioprine
DPYD: 5-FU / Capecitabine Toxicity
Sample: 2-3 ml EDTA Blood / Buccal Swab • TAT: 7-10 Days

Benefits for Physicians:

  • Pre-empt adverse drug reactions (ADRs)
  • Optimize cardiology, psychiatry, and oncology drug selection
  • One-time lifetime test with enduring clinical utility
Section 06

Cytogenetics & Chromosomal Microarray (CMA)

High-resolution cytogenomic solutions for chromosomal structural anomalies, balanced translocations, microdeletions, and unexplained infertility.

Chromosomal Microarray (CMA 750K / CytoScan)

High-density SNP array detecting copy number variations (CNVs) and loss of heterozygosity (LOH) with sub-kilobase resolution.

Sample: 3 ml EDTA Blood / Amniotic Fluid • TAT: 10-12 Days

High-Resolution G-Banded Karyotyping (550+ Bands)

Classical cytogenetic analysis of all 46 chromosomes for translocations, inversions, and marker chromosomes in recurrent pregnancy loss and primary amenorrhea.

Sample: 5 ml Heparin Blood • TAT: 10-14 Days

Recommended For:

  • Multiple congenital anomalies without known cause
  • Developmental delay & intellectual disability
  • Autism Spectrum Disorder (ASD) workup
  • Recurrent miscarriage (couples karyotyping)
Clinical Decision Support Matrix

Genomic Assay Comparison Matrix

Side-by-side comparison of diagnostic yield, target gene resolution, specimen requirements, and turnaround times to aid test selection.

Diagnostic Feature Whole Exome (WES) Clinical Exome (CES) Chromosomal Microarray (CMA) Targeted Panels Karyotyping
Target Genes & Loci ~20,000 Coding Genes 6,500+ OMIM Curated Genes 750,000+ Oligo-SNP Probes 10 – 200 Disease Genes All 46 Chromosomes
Variant Types Detected SNVs, InDels, Exonic CNVs SNVs, Small InDels Sub-microscopic CNVs & LOH Deep SNVs, InDels, Fusions Large Aneuploidies (>5Mb)
Mean Sequencing Depth > 100x Target Coverage > 100x Target Coverage N/A (Array Hybridization) > 500x Ultra-Deep NGS 550+ Band Level
Diagnostic Yield 35% – 45% (Trio Analysis) 25% – 35% 15% – 20% (First-Line) 30% – 50% (Organ-Specific) 3% – 5%
Specimen Tube 3-5 ml EDTA Blood 3 ml EDTA Blood Blood / Amniotic / CVS EDTA Blood / FFPE Tissue Sodium Heparin Blood
Turnaround Time 14 – 18 Working Days 12 – 15 Working Days 10 – 12 Working Days 10 – 14 Working Days 10 – 14 Working Days
Quick Action
Interactive Clinical Sandbox

ACMG / AMP Variant Classifier

Explore how 5-tier clinical pathogenicity scores are computed using standard ACMG criteria combinations.

Class 5: Pathogenic (Clinically Actionable) 4 Evidence Codes Selected

Confirmed high-penetrance disease-causing variant. Initiate targeted clinical management, surveillance protocol, cascade testing for first-degree relatives, and pre-test genetic counseling.

Pathogenic Criteria (Click to Toggle):
PVS1 (Very Strong Null)
PS1 (Same AA Change)
PS2 (De Novo Confirmed)
PS3 (Functional Assay)
PM1 (Hotspot Domain)
PM2 (gnomAD Rarity)
PP3 (In-Silico Deleterious)
PP4 (Phenotype Specific)
Benign Criteria (Click to Toggle):
BA1 (gnomAD Freq > 5%)
BS1 (Higher Freq than Disease)
BS2 (Healthy Adult Controls)
BP4 (In-Silico Benign)
Personalized Precision Prescribing

Pharmacogenomics (PGx) Drug-Gene Explorer

Discover how genetic polymorphisms in drug metabolism enzymes dictate clinical drug efficacy, adverse reaction risks, and CPIC dosing guidelines.

Target Medication

Clopidogrel (Plavix)

Associated Gene CYP2C19
High-Risk Metabolic Phenotype Poor Metabolizer (*2/*2 or *2/*3)
Clinical Consequence & Toxicity Vulnerability

Reduced biotransformation to active thiol metabolite leading to subtherapeutic platelet inhibition and increased risk of Major Adverse Cardiovascular Events (MACE) and Stent Thrombosis.

Clinical Pharmacogenetics (CPIC) Guidelines

CPIC Level A: Avoid clopidogrel. Prescribe alternative antiplatelet agent (Prasugrel or Ticagrelor) in absence of contraindications.

State-of-the-Art Infrastructure

Laboratory Technology & Instrumentation

Explore the high-throughput sequencing systems, automated capillary analyzers, and computational genomics servers powering our Vizag facility.

Ultra-High Throughput Next-Generation Sequencing (NGS)

Illumina NovaSeq 6000 & NextSeq 550 Dx

Powers our Whole Exome, Clinical Exome, and Non-Invasive Prenatal Testing (NIPT) workflows with unprecedented depth, uniformity of coverage, and base calling fidelity.

Sequencing Chemistry 2-Channel & 4-Channel SBS Chemistry with Patterned Flow Cells
Quality Score (Q30) > 85% Bases Above Q30 (>99.9% Base Accuracy)
Maximum Data Yield Up to 6 Terabases per single sequencing run
Target Mean Depth > 100x Exomes / > 500x Somatic Oncology Pan-Cancer Panels

Looking for a Specific Genetic Panel or Assay?

Browse our full searchable test directory or speak directly with our clinical genetics team in Visakhapatnam.

Search 30+ Tests Directory
Lab Helpline (+91 94944 67890)